Orthofix saw net sales of $205.6 million in the third quarter, a 5% increase year over year, according to financial results posted Nov. 4.
Six things to know:
1. Net sales of $205.6 million include revenue from the discontinued M6 artificial disc. Excluding M6, quarterly sales were $203.4 million.
2. U.S. spinal fixation sales increased 8% year over year, and procedure volume grew 10% year over year.
3. Bone growth therapies saw net sales of $61.2 million, a 6% increase year over year.
4. Global orthopedic sales increased 6% year over year with $33.6 million.
5. Orthofix saw a net loss of $22.8 million.
6. Orthofix narrowed its 2025 full-year guidance and expects pro forma net sales to range between $810 million to $814 million.
